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OBJECTIVES: To identify risk factors for significant hepatic dysfunction among
HIV/hepatitis B virus (HBV) or hepatitis C virus (HCV) co-infected patients related to
antiretroviral (ART) exposure.
METHODS: All HIV Ontario Observational Database (HOOD) patients that were
chronic carriers of HBV or HCV were identified. ART medication and laboratory
adverse event data were obtained through bi-annual chart reviews.
RESULTS: Four-hundred-and-four HIV-positive patients were identified as co-infected
with HCV (n=317), HBV (n=104) or both HCV and HBV (n=17). Two hundred and forty-
three (60%) and 249 (62%) of these patients had ever had grade 3 or 4 elevations in
alanine aminotransferase (ALT) and aspartate aminotransferase (AST), respectively,
versus 676 (41%) and 673 (41%) (P<0.001 and P<0.001) of those with HIV not co-
infected. The median [interquartile range (IQR)] duration of infection with HCV and/or
HBV at the time of initial identification of elevations in transaminases (AST/ALT) was
842 days (260–1780). The median (IQR) time after starting any ART to the
development of grade 3 or 4 hepatic dysfunction was 896 days (216–1680). Grade 3 or
4 elevations in AST/ALT were significantly associated with ever taking: a boosted
protease inhibitor (PI) (72% vs 59%, P=0.01), ritonavir (70% vs 51%, P=0.0001) and/or
didanosine (ddI) (66% vs 56%, P=0.03), and a trend with ever taking stavudine (d4T)
(63% vs 54%, P=0.06), but not with taking a nelfinavir-based regimen without previous
exposure to ritonavir, d4T and/or ddI (61% vs 62%, P=0.96). Patients who had ever
had grade 3 or 4 elevations in ALT/AST also had exposure to higher median numbers
of all types of ARTs (6 vs 5, P<0.001), nucleoside reverse transcriptase inhibitors (4 vs
3, P=0.001), non-nucleoside reverse transcriptase inhibitors (1 vs 0, P=0.004) and PIs
(2 vs 1, P=0.002).CONCLUSION: A high proportion of HIV patients co-infected with HBV and HCV have
serious elevations in transaminases which may be related to both type and cumulative
exposure to ART. Patients exposed to boosted PI regimens, ddI and d4T appear to be
at heightened risk, and patients on nelfinavir-based regimens without previous
exposure to other PIs or ddI/d4T at lower risk, for serious hepatotoxicity.
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